Literature DB >> 15162124

Remarkable variability in renal disease in a large Slovenian family with Fabry disease.

Franc Verovnik1, Davorin Benko, Bojan Vujkovac, Gabor E Linthorst.   

Abstract

Following the diagnosis of Fabry disease in a 45-year-old male, in 31 family members alpha-galactosidase A (alpha-Gal) activity in leucocytes was measured and mutation analysis of the alpha-Gal gene was performed. In the proband, the unique mutation A10523G/N272S in exon 6 was found, which was subsequently detected in seven males (of which one twin) and 10 female subjects. All males showed decreased to absent alpha-Gal A activity in leucocytes, but three out of 10 female subjects had alpha-Gal A activities within normal range. Although all male patients had symptoms of classical Fabry disease, such as acroparesthesias, hypohydrosis and heat-intolerance, there was considerable variability in organ involvement, especially in deterioration of renal function. Detailed studies of large families with Fabry disease may give insight into factors that influence the phenotype of this disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162124     DOI: 10.1038/sj.ejhg.5201184

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  15 in total

1.  The Impact of Fabry Disease on Reproductive Fitness.

Authors:  Dawn A Laney; Virginia Clarke; Allison Foley; Eric W Hall; Scott E Gillespie; Myrl Holida; Morgan Simmons; Alexandrea Wadley
Journal:  JIMD Rep       Date:  2017-03-22

2.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

3.  Structural characterization of mutant alpha-galactosidases causing Fabry disease.

Authors:  Kanako Sugawara; Kazuki Ohno; Seiji Saito; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-07-17       Impact factor: 3.172

4.  Different renal phenotypes in related adult males with Fabry disease with the same classic genotype.

Authors:  Renzo Mignani; Mariarita Moschella; Giovanna Cenacchi; Ilaria Donati; Marta Flachi; Daniela Grimaldi; Davide Cerretani; Paola De Giovanni; Marcello Montevecchi; Angelo Rigotti; Alessandro Ravasio
Journal:  Mol Genet Genomic Med       Date:  2017-05-08       Impact factor: 2.183

Review 5.  Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease.

Authors:  Yuan Wu; Hong Xia; Jinzhong Yuan; Hongbo Xu; Xiong Deng; Jun Liu; Hao Zhang; Hao Deng
Journal:  Curr Genomics       Date:  2018-01       Impact factor: 2.236

Review 6.  Genetic Factors of Cerebral Small Vessel Disease and Their Potential Clinical Outcome.

Authors:  Vo Van Giau; Eva Bagyinszky; Young Chul Youn; Seong Soo A An; Sang Yun Kim
Journal:  Int J Mol Sci       Date:  2019-09-03       Impact factor: 5.923

7.  Descriptive epidemiology of Fabry disease among beneficiaries of the Specified Disease Treatment Research Program in Japan.

Authors:  Kazuya Tsuboi; Sadao Suzuki; Masaki Nagai
Journal:  J Epidemiol       Date:  2012-06-09       Impact factor: 3.211

8.  Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).

Authors:  Can Ficicioglu; Roberto Giugliani; Paul Harmatz; Nancy J Mendelsohn; Virginie Jego; Rossella Parini
Journal:  Am J Med Genet A       Date:  2017-12-06       Impact factor: 2.802

9.  Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease.

Authors:  Antonino Tuttolomondo; Irene Simonetta; Giovanni Duro; Rosaria Pecoraro; Salvatore Miceli; Paolo Colomba; Carmela Zizzo; Antonia Nucera; Mario Daidone; Tiziana Di Chiara; Rosario Scaglione; Vittoriano Della Corte; Francesca Corpora; Danai Vogiatzis; Antonio Pinto
Journal:  Oncotarget       Date:  2017-05-29

Review 10.  Biomarkers of Fabry Nephropathy: Review and Future Perspective.

Authors:  Tina Levstek; Bojan Vujkovac; Katarina Trebusak Podkrajsek
Journal:  Genes (Basel)       Date:  2020-09-18       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.